Replimune Group (NASDAQ:REPL) PT Lowered to $14.00

Replimune Group (NASDAQ:REPL – Get Free Report) had its price objective reduced by research analysts at JPMorgan Chase & Co. from $17.00 to $14.00 in a report issued on Tuesday, Benzinga reports. The firm presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective points to a potential upside of 46.60% […]

Leave a Reply

Your email address will not be published.

Previous post Y-mAbs Therapeutics’ (YMAB) “Buy” Rating Reaffirmed at HC Wainwright
Next post Oppenheimer Cuts Perspective Therapeutics (NYSE:CATX) Price Target to $17.00